Article

A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2

2023-09-30

Abstract excerpt

(1) Background: We previously reported the development of a recombinant protein SARS-CoV-2 vaccine, consisting of the Receptor-Binding Domain (RBD) of the SARS-CoV-2 spike protein, adjuvanted with aluminum hydroxide (alum) and CpG oligonucleotides. In mice and non-human primates, our wild-type (WT) RBD vaccine induced high neutralizing antibody titers against the WT isolate of the virus, and, with partners in Indi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7cff20a2-e71d-5c36-a084-21114de91e4d
DOI: 10.20944/preprints202309.0139.v4

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2DOI 10.20944/preprints202309.0139.v4Read

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity Read

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 VaccineSemantic proximity Read

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernSemantic proximity Read

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2Semantic proximity Read

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamstersSemantic proximity Read

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1Semantic proximity Read

Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamstersSemantic proximity Read

Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1Semantic proximity Read

Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 VaccineSemantic proximity Read

Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platformSemantic proximity Read

Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2Semantic proximity Read

Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBDSemantic proximity Read